143 related articles for article (PubMed ID: 32772232)
21. A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study.
Fizazi K; Delva R; Caty A; Chevreau C; Kerbrat P; Rolland F; Priou F; Geoffrois L; Rixe O; Beuzeboc P; Malhaire JP; Culine S; Aubelle MS; Laplanche A
Eur Urol; 2014 Feb; 65(2):381-6. PubMed ID: 24094847
[TBL] [Abstract][Full Text] [Related]
22. Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor.
Kojima T; Kawai K; Tsuchiya K; Abe T; Shinohara N; Tanaka T; Masumori N; Yamada S; Arai Y; Narita S; Tsuchiya N; Habuchi T; Nishiyama H
Int J Urol; 2015 Oct; 22(10):923-7. PubMed ID: 26094715
[TBL] [Abstract][Full Text] [Related]
23. Dose-dense chemotherapy for untreated poor-prognosis and relapsed germ-cell tumours: an 18-year experience with GAMEC chemotherapy.
Shamash J; Mee M; Sarker SJ; Wilson P; Ansell W; Greenwood M; Berney D; Alifrangis C
BJU Int; 2020 Jun; 125(6):843-852. PubMed ID: 31688976
[TBL] [Abstract][Full Text] [Related]
24. [Result of treatment for advanced germ cell tumor in the last decade].
Ishioka J; Kageyama Y; Inoue M; Fukui N; Numao N; Saito K; Ichiyanagi N; Tanak M; Hyochi N; Fukuda H; Higashi Y
Nihon Hinyokika Gakkai Zasshi; 2010 Mar; 101(3):539-46. PubMed ID: 20387513
[TBL] [Abstract][Full Text] [Related]
25. Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors.
Albany C; Adra N; Snavely AC; Cary C; Masterson TA; Foster RS; Kesler K; Ulbright TM; Cheng L; Chovanec M; Taza F; Ku K; Brames MJ; Hanna NH; Einhorn LH
Ann Oncol; 2018 Feb; 29(2):341-346. PubMed ID: 29140422
[TBL] [Abstract][Full Text] [Related]
26. The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer.
Ribnikar D; Stukalin I; Bedard PL; Hamilton RJ; Jewett M; Warde P; Chung P; Anson-Cartwright L; Templeton AJ; Amir E; Hansen AR; Heng DYC; Lewin J
Curr Oncol; 2020 Dec; 28(1):107-114. PubMed ID: 33622996
[TBL] [Abstract][Full Text] [Related]
27. Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group.
Winter C; Pfister D; Busch J; Bingöl C; Ranft U; Schrader M; Dieckmann KP; Heidenreich A; Albers P
Eur Urol; 2012 Feb; 61(2):403-9. PubMed ID: 22078334
[TBL] [Abstract][Full Text] [Related]
28. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP).
Culine S; Kerbrat P; Kramar A; Théodore C; Chevreau C; Geoffrois L; Bui NB; Pény J; Caty A; Delva R; Biron P; Fizazi K; Bouzy J; Droz JP;
Ann Oncol; 2007 May; 18(5):917-24. PubMed ID: 17351252
[TBL] [Abstract][Full Text] [Related]
29. Excellent survival in relapsed stage I testicular cancer.
Speicher P; Fankhauser CD; Lorch A; Ardizzone D; Helnwein S; Hoch D; Hermanns T; Beyer J; Akhoundova D
BMC Cancer; 2023 Sep; 23(1):870. PubMed ID: 37715132
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of men with HIV and germ cell cancer: Results from an international collaborative study.
Hentrich MU; Bower M; Daugaard G; Dieing A; Bickel M; Berretta M; Lesmeister F; Jurinovic V; Stoehr A; Heinzelbecker J; Krznaric I; Dieckmann KP; Necchi A; Maroto Rey P; Rockstroh JK; Brito M; Pfister D; Hoffmann C
Cancer; 2022 Jan; 128(2):260-268. PubMed ID: 34592009
[TBL] [Abstract][Full Text] [Related]
31. Stage migration and pilot studies of reduced chemotherapy supported by positron-emission tomography findings suggest new combined strategies for stage 2 nonseminoma germ cell tumour.
Haba Y; Williams MV; Neal DE; Ong JY; Ostrowski MJ; Ell PJ; Nargund V; Shamash J; Oliver RT
BJU Int; 2008 Mar; 101(5):570-4. PubMed ID: 18257857
[TBL] [Abstract][Full Text] [Related]
32. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
33. A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial.
Fizazi K; Do KA; Wang X; Finn L; Logothetis CJ; Amato RJ
Ann Oncol; 2002 Jan; 13(1):125-34. PubMed ID: 11863094
[TBL] [Abstract][Full Text] [Related]
34. Effect of the timing of orchiectomy on survival in patients with metastatic germ cell tumors of testis.
Fedyanin M; Tryakin A; Bulanov A; Fainshtein I; Zakharova T; Matveev V; Garin A; Tjulandin S
Urol Oncol; 2014 Jan; 32(1):32.e27-33. PubMed ID: 23628310
[TBL] [Abstract][Full Text] [Related]
35. Methotrexate, paclitaxel, ifosfamide, and cisplatin in poor-risk nonseminomatous germ cell tumors.
Pectasides D; Pectasides E; Papaxoinis G; Xiros N; Kamposioras K; Tountas N; Economopoulos T
Urol Oncol; 2010; 28(6):617-23. PubMed ID: 19110454
[TBL] [Abstract][Full Text] [Related]
36. E400P in advanced seminoma of good prognosis according to the international germ cell cancer collaborative group (IGCCCG) classification: the Spanish Germ Cell Cancer Group experience.
Arranz Arija JA; García del Muro X; Gumà J; Aparicio J; Salazar R; Saenz A; Carles J; Sánchez M; Germà-Lluch JR
Ann Oncol; 2001 Apr; 12(4):487-91. PubMed ID: 11398880
[TBL] [Abstract][Full Text] [Related]
37. Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy.
Sammler C; Beyer J; Bokemeyer C; Hartmann JT; Rick O
Eur J Cancer; 2008 Jan; 44(2):237-43. PubMed ID: 18055194
[TBL] [Abstract][Full Text] [Related]
38. The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients.
Bhala N; Coleman JM; Radstone CR; Horsman JM; George J; Hancock BW; Hatton MQ; Coleman RE
Clin Oncol (R Coll Radiol); 2004 Feb; 16(1):40-7. PubMed ID: 14768754
[TBL] [Abstract][Full Text] [Related]
39. Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management.
Liu YL; Manning-Geist BL; Knezevic A; Deng L; Bromberg M; Funt SA; Meisel JL; Zivanovic O; Roche KL; Sonoda Y; Gardner GJ; Grisham RN; O'Cearbhaill RE; Tew WP; Abu-Rustum NR; Chi DS; Aghajanian C; Feldman DR
Gynecol Oncol; 2023 Mar; 170():93-101. PubMed ID: 36669327
[TBL] [Abstract][Full Text] [Related]
40. Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group.
Aparicio J; Sánchez-Muñoz A; Ochenduszko S; Gumà J; Fernández-Aramburo A; García Del Muro X; Quiroga V; Sastre J; Alonso-Gordoa T; Sagastibelza N; Maroto P; Gómez de Liaño A; Vázquez S; Diz P; Durán I; Domenech M; Pinto A; Hernández A; González-Billalabeitia E; Terrasa J
J Urol; 2019 Oct; 202(4):742-747. PubMed ID: 31163007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
